BTK and B-cell chronic lymphocytic leukemia: Preliminary combination treatment of the novel PI3Kδ inhibitor zandelisib (MEI-401) with the BTK inhibitor zanubrutinib in relapsed or refractory CLL resulted in a complete response rate and was well tolerated, although only 5 patients were enrolled [94].